Fundz

Amgen

Biotechnology, Health Care · 38,884 employees

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds o

Recent signals

  • Mar 14, 2026: Amgen Inc. Appoints Olivier Leonetti as Chief Financial Officer
  • Jan 30, 2026: Amgen Inc. Terminates License and Collaboration Agreement with Kyowa Kirin
  • Jan 30, 2026: SEC 8-K (1.02): On January 30, 2026, Amgen Inc. entered into a Termination Agreement with Kyowa Kirin Co., Ltd. to terminate their License and Collaboration Agreement originally dated June 1, 2021. The termination will take effect upon receipt of regulatory approval. This action signifies the end of their collaboration, which may impact their joint projects and strategies moving forward. Further details are found in the Termination Agreement filed as Exhibit 10.1 with this report.
  • Jan 06, 2026: Acquired Amgen acquires Dark Blue Therapeutics for $840M
  • Jun 22, 2025: KPMG Women’s Irish Open secures two-year partnership extension with Amgen to promote women's sport.
  • Feb 02, 2025: NJ's Largest Hospital System Ends In-Network Partnership With Horizon
  • Jan 06, 2025: Launched Amgen Launches IMDYLLTRA® for the Treatment of Extensive-Stage Small Cell Lung Cancer in the UK
  • Nov 20, 2024: Amgen Appoints Howard Chang, M.D., Ph.D., as Senior Vice President of Research and Chief Scientific Officer

See plans & pricing → Track Amgen’s funding, hiring, and signals — with verified contacts — on Fundz.